drugset / Trial / NCT07776132
Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind, parallel-controlled study to compare the PK profile of HLX29 and HLX11 and evaluate their safety, tolerability, and immunogenicity after a single intravenous dose in healthy male adult participants.
Timeline
- Start
- 2026-11-05
- Primary completion
- 2027-01-31
- Completion
- 2027-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | HLX11 | Monoclonal antibody | — | Intravenous |
| Subject | HLX29 | Unknown | — | Intravenous |
Indications
No indication recorded.